241 related articles for article (PubMed ID: 30347827)
1. Oncotoxic Properties of Serotonin Transporter Inhibitors and 5-HT
Walory J; Mielczarek L; Jarończyk M; Koronkiewicz M; Kossakowski J; Bugno R; Bojarski AJ; Chilmonczyk Z
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347827
[TBL] [Abstract][Full Text] [Related]
2. Dual actions of 5-MeO-DIPT at the serotonin transporter and serotonin 5-HT
Hagino Y; Hall FS; Uhl GR; Sora I; Ikeda K
Neuropsychopharmacol Rep; 2021 Mar; 41(1):91-101. PubMed ID: 33547882
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output.
van Amsterdam C; Seyfried CA
Psychopharmacology (Berl); 2014 Jun; 231(12):2547-58. PubMed ID: 24419272
[TBL] [Abstract][Full Text] [Related]
4. Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT(1A) activity. part 3.
Herold F; Chodkowski A; Izbicki Ł; Turło J; Dawidowski M; Kleps J; Nowak G; Stachowicz K; Dybała M; Siwek A; Mazurek AP; Mazurek A; Pluciński F
Eur J Med Chem; 2011 Jan; 46(1):142-9. PubMed ID: 21093118
[TBL] [Abstract][Full Text] [Related]
5. Effects of the potential antidepressant OPC-14523 [1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2-quinolinone monomethanesulfonate] a combined sigma and 5-HT1A ligand: modulation of neuronal activity in the dorsal raphe nucleus.
Bermack JE; Haddjeri N; Debonnel G
J Pharmacol Exp Ther; 2004 Aug; 310(2):578-83. PubMed ID: 15044555
[TBL] [Abstract][Full Text] [Related]
6. 5-HT1A agonist alleviates serotonergic potentiation of extrapyramidal disorders via postsynaptic mechanisms.
Shimizu S; Mizuguchi Y; Tatara A; Kizu T; Andatsu S; Sobue A; Fujiwara M; Morimoto T; Ohno Y
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():86-91. PubMed ID: 23838274
[TBL] [Abstract][Full Text] [Related]
7. Activation of 5-HT1A Receptors Promotes Retinal Ganglion Cell Function by Inhibiting the cAMP-PKA Pathway to Modulate Presynaptic GABA Release in Chronic Glaucoma.
Zhou X; Zhang R; Zhang S; Wu J; Sun X
J Neurosci; 2019 Feb; 39(8):1484-1504. PubMed ID: 30541912
[TBL] [Abstract][Full Text] [Related]
8. Functional interactions between 5-HT2A and presynaptic 5-HT1A receptor-based responses in mice genetically deficient in the serotonin 5-HT transporter (SERT).
Fox MA; Stein AR; French HT; Murphy DL
Br J Pharmacol; 2010 Feb; 159(4):879-87. PubMed ID: 20128812
[TBL] [Abstract][Full Text] [Related]
9. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.
Hughes ZA; Starr KR; Langmead CJ; Hill M; Bartoszyk GD; Hagan JJ; Middlemiss DN; Dawson LA
Eur J Pharmacol; 2005 Mar; 510(1-2):49-57. PubMed ID: 15740724
[TBL] [Abstract][Full Text] [Related]
10. Activation of 5-HT
Tavares LRR; Baptista-de-Souza D; Canto-de-Souza A
Neuropharmacology; 2018 Jun; 135():376-385. PubMed ID: 29548885
[TBL] [Abstract][Full Text] [Related]
11. Discovery of DSP-1053, a novel benzylpiperidine derivative with potent serotonin transporter inhibitory activity and partial 5-HT
Yoshinaga H; Nishida T; Sasaki I; Kato T; Oki H; Yabuuchi K; Toyoda T
Bioorg Med Chem; 2018 May; 26(8):1614-1627. PubMed ID: 29456112
[TBL] [Abstract][Full Text] [Related]
12. Mutant 5-hydroxytryptamine 1A receptor D116A is a receptor activated solely by synthetic ligands with a rich pharmacology.
Cussac D; Palmier C; Finana F; De Vries L; Tardif S; Léger C; Bernois S; Heusler P
J Pharmacol Exp Ther; 2009 Oct; 331(1):222-33. PubMed ID: 19605522
[TBL] [Abstract][Full Text] [Related]
13. Bell-shaped agonist activation of 5-HT
Newman-Tancredi A; Cussac D; Ormière AM; Lestienne F; Varney MA; Martel JC
Cell Signal; 2019 Nov; 63():109383. PubMed ID: 31376526
[TBL] [Abstract][Full Text] [Related]
14. Differential involvement of 5-HT(1A) and 5-HT(1B/1D) receptors in human interferon-alpha-induced immobility in the mouse forced swimming test.
Zhang H; Wang W; Jiang Z; Shang J; Zhang L
Arzneimittelforschung; 2010; 60(3):109-15. PubMed ID: 20422941
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
Bang-Andersen B; Ruhland T; Jørgensen M; Smith G; Frederiksen K; Jensen KG; Zhong H; Nielsen SM; Hogg S; Mørk A; Stensbøl TB
J Med Chem; 2011 May; 54(9):3206-21. PubMed ID: 21486038
[TBL] [Abstract][Full Text] [Related]
16. Antidepressant-like activity of YL-0919: a novel combined selective serotonin reuptake inhibitor and 5-HT1A receptor agonist.
Chen HX; Jin ZL; Zhang LM; Xue R; Xu XD; Zhao N; Qiu ZK; Wang XW; Zhang YZ; Yang RF; Li YF
PLoS One; 2013; 8(12):e83271. PubMed ID: 24367588
[TBL] [Abstract][Full Text] [Related]
17. Effects of 5-HT
Fletcher PJ; Zeeb FD; Browne CJ; Higgins GA; Soko AD
Psychopharmacology (Berl); 2017 Mar; 234(5):889-902. PubMed ID: 28097374
[TBL] [Abstract][Full Text] [Related]
18. SB-649915, a novel, potent 5-HT1A and 5-HT1B autoreceptor antagonist and 5-HT re-uptake inhibitor in native tissue.
Scott C; Soffin EM; Hill M; Atkinson PJ; Langmead CJ; Wren PB; Faedo S; Gordon LJ; Price GW; Bromidge S; Johnson CN; Hagan JJ; Watson J
Eur J Pharmacol; 2006 Apr; 536(1-2):54-61. PubMed ID: 16571351
[TBL] [Abstract][Full Text] [Related]
19. Analysis of mechanisms for memory enhancement using novel and potent 5-HT1A receptor ligands.
Pittalà V; Siracusa MA; Salerno L; Romeo G; Modica MN; Madjid N; Ogren SO
Eur Neuropsychopharmacol; 2015 Aug; 25(8):1314-23. PubMed ID: 25963581
[TBL] [Abstract][Full Text] [Related]
20. The role of activation of the 5-HT1A receptor and adenylate cyclase in the antidepressant-like effect of YL-0919, a dual 5-HT1A agonist and selective serotonin reuptake inhibitor.
Qin JJ; Chen HX; Zhao N; Yuan L; Zhang YZ; Yang RF; Zhang LM; Li YF
Neurosci Lett; 2014 Oct; 582():104-8. PubMed ID: 25220701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
